Publications by authors named "R Lhote"
Objectives: Lymphadenopathy is a classical manifestation of systemic lupus erythematosus (SLE) flare, occurring in approximately half of patients during the course of the disease. Lymphadenopathy in SLE is frequently associated with fever. Microbial infection may play a role in SLE onset and flares.
View Article and Find Full Text PDFArticle Synopsis
- Primary chronic Non-Bacterial Osteomyelitis of the jaw is a rare inflammatory disease that shares similarities with SAPHO syndrome and chronic recurrent multifocal osteomyelitis, and TNF-alpha blockade may be an effective treatment option despite limited clinical data.
- In a study of 15 patients with refractory CNOM, 10 were treated with anti-TNF-alpha therapy due to previous treatment failures and the promising efficacy seen in related conditions.
- The results showed that most patients experienced rapid and lasting remission without serious side effects, though male patients appeared to have poorer outcomes, indicating that TNF-alpha blockade is both safe and effective for CNOM management.
Objective: Previous studies have provided evidence that the discontinuation of hydroxychloroquine (HCQ), and chloroquine (CQ), in patients with systemic lupus erythematosus (SLE) is associated with an increased risk of disease flares, with limited information on the level of disease activity at the time of HCQ/CQ discontinuation. Here we aimed to describe the risk of SLE flare after withdrawal of HCQ or CQ in patients with SLE in remission.
Methods: Case-control study (1:2) comparing the evolution of patients with SLE after HCQ/CQ withdrawal for antimalarial retinopathy (cases) with patients with SLE matched for sex, antimalarial treatment duration and age at SLE diagnosis, whose antimalarial treatment was continued throughout the entire follow-up period (controls).
Background: Long-term hydroxychloroquine (HCQ) or chloroquine (CQ) intake causes retinal toxicity in 0.3-8 % of patients with rheumatic diseases. Numerous risk factors have been described, eg, daily dose by weight, treatment duration, chronic kidney disease, concurrent tamoxifen therapy and pre-existing retinal or macular disease.
View Article and Find Full Text PDF